Lilly lost the first round in its patent-infringement battle with Ariad Pharmaceuticals, which was granted a $65.2 million award. The award includes a 2.3% royalty on all sales of Lilly drugs Evista and Xigris, until Ariad’s patent expires in 2019. The suit was based on a patent held by Ariad and co-plaintiffs MIT, Harvard, and the Whitehead Institute covering regulation of the NF-KB cellular pathway, a method that Evista and Xigris both employ. Lilly contends that the patent should nev...